Functional and Clinical Analysis of Rak in Breast Cancer Suppression
Functional and Clinical Analysis of Rak in Breast Cancer Suppression
批准号:
7534995
负责人:
Shiaw-Yih Lin
金额:
$26.33万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-05 至 2011-11-30
关键词:
6q21Cancer cell lineCell Cycle ArrestCell Cycle CheckpointCell LineCell NucleusCellsChromosome abnormalityChromosomesClinicalCore FacilityDNADNA DamageDNA damage checkpointDataDevelopmentEpigenetic ProcessEpithelial CellsGenome StabilityGenomic InstabilityGenomicsGenotoxic StressHumanKnockout MiceLoss of HeterozygosityMaintenanceMalignant NeoplasmsMammary NeoplasmsMammary glandMediatingMutationNuclearNucleic AcidsPathologicPatientsPlayProcessPrognostic MarkerProliferatingProtein AnalysisProteinsRadiationReceptor Protein-Tyrosine KinasesResearch PersonnelRoleSamplingSignal TransductionSpectral KaryotypingTelomeraseTestingTherapeuticTimeTissuesTumor BankTumor Suppressor Genesbasecancer initiationcell immortalizationchromatin immunoprecipitationcomparative genomic hybridizationimprovedin vivoirradiationmalignant breast neoplasmmetaplastic cell transformationmouse modelnovelpreventprogramspromoterresponsesmall hairpin RNAtherapeutic targettransmission processtumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Loss of cell cycle checkpoint control and acquisition of the ability to proliferate indefinitely constitute two
of the fundamental changes required for the development of cancer. Rak, a non-receptor tyrosine kinase
identified through our enhanced retroviral mutation screen as a represser of hTERT function, has been
implicated in cellular immortalization. Our preliminary data indicate that Rak has additional functions in the
transmission of DNA damage signals and is required for intact DNA damage checkpoints. Moreover, Rak is
located on chromosome 6q21-23, a region that undergoes loss of heterozygosity in 30% of breast cancer
cases. Rak expression is also significantly reduced in breast cancer tissues and cancer cell lines as
analyzed by DNA arrays, real-time PCR, and protein analysis. Thus, we hypothesize that Rak may function
as a tumor suppressor gene in breast cancer through dual functions: repressing cellular immortalization and
maintaining genomic stability. This hypothesis will be tested in the following steps. (1) We will determine the
role of Rak in preventing cellular immortalization by using normal human mammary epithelial cells that
conditionally express small hairpin RNA against Rak, and we will investigate the mechanisms mediating
Rak's function on hTERT expression. (2) We will use Rak-depleted cells to study the role of Rak in the
response to genotoxic stress, maintenance of genomic integrity, and cellular transformation; for these
studies, we will assess genomic instability by using comparative genomic hybridization (CGH) and spectral
karyotyping (SKY) to visualize chromosomal aberrations; we will study how Rak may participate directly in
transmitting DNA damage signals; and we will use a knockout mouse model to assess Rak's function in vivo
in maintaining genomic integrity and suppressing tumor formation. (3) We will identify and characterize
aberrations in Rak in samples from patients with breast cancer to determine if Rak serves as a prognostic
marker or a therapeutic target in cancer. As a corollary, analyzing the function of Rak and its aberrations in
patients with cancer will contribute to an improved understanding of the key pathologic alterations in cancer
initiation and progression and to the development of novel, effective therapeutic approaches for cancer.
Relevance: Rak plays a dual role in preventing cell immortalization and maintaining genomic stability.
Our studies have identified Rak as a potentially important tumor suppressor gene in breast cancer. An
analysis of the function of Rak and its network of interacting proteins will clarify the key pathologic alterations
in cancer initiation and progression and eventually will aid in the development of novel, effective therapeutic
approaches for breast cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer
-
批准号:10556413
-
项目类别:
-
资助金额:$36.2万
-
财政年份:2021
-
负责人:Shiaw-Yih Lin
-
依托单位:
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer
-
批准号:10330595
-
项目类别:
-
资助金额:$36.2万
-
财政年份:2021
-
负责人:Shiaw-Yih Lin
-
依托单位:
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer
-
批准号:10117861
-
项目类别:
-
资助金额:$36.94万
-
财政年份:2021
-
负责人:Shiaw-Yih Lin
-
依托单位:
RNase H2 is a novel therapeutic target in triple negative breast cancer
-
批准号:10437893
-
项目类别:
-
资助金额:$37.64万
-
财政年份:2021
-
负责人:Shiaw-Yih Lin
-
依托单位:
RNase H2 is a novel therapeutic target in triple negative breast cancer
-
批准号:10658881
-
项目类别:
-
资助金额:$37.64万
-
财政年份:2021
-
负责人:Shiaw-Yih Lin
-
依托单位:
RNase H2 is a novel therapeutic target in triple negative breast cancer
-
批准号:10297432
-
项目类别:
-
资助金额:$38.41万
-
财政年份:2021
-
负责人:Shiaw-Yih Lin
-
依托单位:
Signature-guided therapy for mismatch repair defective cancers
-
批准号:9977136
-
项目类别:
-
资助金额:$37.33万
-
财政年份:2017
-
负责人:Shiaw-Yih Lin
-
依托单位:
Signature-guided therapy for mismatch repair defective cancers
-
批准号:10215252
-
项目类别:
-
资助金额:$37.33万
-
财政年份:2017
-
负责人:Shiaw-Yih Lin
-
依托单位:
Signature-guided therapy for mismatch repair defective cancers
-
批准号:9751230
-
项目类别:
-
资助金额:$36.21万
-
财政年份:2017
-
负责人:Shiaw-Yih Lin
-
依托单位:
Signature-guided therapy for mismatch repair defective cancers
-
批准号:9361858
-
项目类别:
-
资助金额:$37.33万
-
财政年份:2017
-
负责人:Shiaw-Yih Lin
-
依托单位:
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer
-
批准号:8792837
-
项目类别:
-
资助金额:$32.3万
-
财政年份:2013
-
负责人:Shiaw-Yih Lin
-
依托单位:
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer
-
批准号:9206478
-
项目类别:
-
资助金额:$32.3万
-
财政年份:2013
-
负责人:Shiaw-Yih Lin
-
依托单位:
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer
-
批准号:8421980
-
项目类别:
-
资助金额:$32.3万
-
财政年份:2013
-
负责人:Shiaw-Yih Lin
-
依托单位:
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer
-
批准号:8610904
-
项目类别:
-
资助金额:$31.93万
-
财政年份:2013
-
负责人:Shiaw-Yih Lin
-
依托单位:
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer
-
批准号:8997467
-
项目类别:
-
资助金额:$32.3万
-
财政年份:2013
-
负责人:Shiaw-Yih Lin
-
依托单位:
Functional and Clinical Analysis of Rak in Breast Cancer Suppression
-
批准号:7324804
-
项目类别:
-
资助金额:$26.33万
-
财政年份:2006
-
负责人:Shiaw-Yih Lin
-
依托单位:
Functional and Clinical Analysis of Rak in Breast Cancer Suppression
-
批准号:7746451
-
项目类别:
-
资助金额:$26.33万
-
财政年份:2006
-
负责人:Shiaw-Yih Lin
-
依托单位:
Functional and Clinical Analysis of Rak in Breast Cancer Suppression
-
批准号:7210323
-
项目类别:
-
资助金额:$26.33万
-
财政年份:2006
-
负责人:Shiaw-Yih Lin
-
依托单位:
Functional and Clinical Analysis of Rak in Breast Cancer Suppression
-
批准号:7989999
-
项目类别:
-
资助金额:$25.54万
-
财政年份:2006
-
负责人:Shiaw-Yih Lin
-
依托单位:
BRIT 1: Roles in Immortalization, Checkpoints and Cancer
-
批准号:7394970
-
项目类别:
-
资助金额:$25.28万
-
财政年份:2005
-
负责人:Shiaw-Yih Lin
-
依托单位:
海外基金